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Hospital-acquired pneumonia (HAP) is pneumonia occurring ≥48 hours after 
admission; it is the most common hospital-acquired infection contributing to death. 
Ventilator-associated pneumonia (VAP) arises ≥48-72 hours after intubation. 
Opinions differ on whether VAP is a HAP subset; the same pathogens predominate in 
both. Compared with VAP-free controls, patients developing VAP are twice as likely to 
die, and have significantly longer ICU stays. 
Guidelines recommend that microbiological cultures should guide antibiotic treatment, 
but these lack sensitivity and take 48-72 hours to process, meaning that initial therapy 
must be empiric, generally with broad-spectrum agents. Given increasing pressure to 
improve both antibiotic stewardship and patient outcomes, the National Institute for 
Health and Care Excellence, and the Infectious Diseases Society of America 
recommend research into rapid molecular diagnostic tests to identify causative 
organisms and their antibiotic resistances. Ideally, these would supersede culture, 
being quicker and more sensitive. The United Kingdom’s National Institute for Health 
Research-funded INHALE research programme is exploring rapid molecular 
diagnostics to inform treatment of HAP/VAP and, given resource implications, 













Twenty studies identified. Only one specifically evaluated strategies to improve 




HAP/VAP modelling would be improved by better awareness of long-term outcomes 
and treatment complexity. We are unaware of any similar literature reviews of 
economic modelling for HAP/VAP. 
[244 words] 
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Abbreviations 
ARC EoE Applied Research Collaboration East of England 
CAP Community-acquired pneumonia 
CI Confidence interval 
EED Economic Evaluation Database 
ETT Endotracheal tube 
HAP Hospital acquired pneumonia 
HE Health economics 
ICER Incremental cost-effectiveness ratio 
ICU Intensive care unit 
IDSA Infectious Diseases Society of America 
LOS Length of stay 
MIC Minimum inhibitory concentration 
MRSA Methicillin-resistant Staphylococcus aureus 
MSSA Methicillin-sensitive Staphylococcus aureus 
NA Not applicable 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
NIHR National Institute for Health Research 
NR Not reported 
PCR Polymerase chain reaction 
PSA Probabilistic Sensitivity Analysis 
QALY Quality adjusted life year 
SA Sensitivity analysis 
UK United Kingdom 
VAP Ventilator-associated pneumonia 
WTP Willingness to pay 
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‘Hospital-acquired pneumonia’ (HAP) is pneumonia that occurs ≥48 hours after 
admission and was not incubating at admission [1, 2]. ‘Ventilator-associated 
pneumonia (VAP) is ‘pneumonia that arises more than 48-72 hours after 
endotracheal intubation’ [1, p.389]. Opinions differ on whether VAP is a subset of 
HAP or a separate entity [1, 2]; nevertheless, both are difficult to treat, often involving 
pathogens with significant antibiotic resistance [3]. 
HAP occurs in 0.5-1.5% of inpatients [2, 4] and is the most common hospital- 
acquired infection contributing to death [5]. One study estimated HAP to increase 
mean hospitalisation duration by nine days [6]. A systematic review estimated that 
VAP develops in 10-20% of patients receiving ≥48 hours of mechanical ventilation 
[7], and that – compared to VAP-free controls – VAP patients are twice as likely to 
die, have significantly longer ICU stays, and create substantial additional hospital 
costs. 
Multiple guidelines exist on prevention, diagnosis and treatment of HAP/VAP, but 
have poor underpinning evidence [8]. Preparing UK 2008 guidelines, Masterton et al. 
[4] undertook a systematic literature review of HAP prevention, diagnosis and 
treatment. They described the then American Thoracic Society guidelines [1] as 
extensive and evidence based but with shortcomings. The most recent US and 
European (2016 and 2017 respectively) guidelines [8, 9], continue to have many 
recommendations caveated as ‘weak recommendation’ or ‘very low-quality’ 
evidence. 
These guidelines nonetheless agree on the broad HAP treatment strategy: doctors 
should give ‘empirical’ antibiotics immediately on suspecting HAP, with the choice 
informed by local pathogen prevalence and resistance rates, along with patient 
factors. Respiratory and blood samples should be taken before antibiotic initiation 
and the resulting culture and susceptibility results, once available, should guide 
‘definitive’ antibiotic choice. Antibiotics may be changed based upon the patient’s 
response, secondary infections and/or other clinical factors. 
Culture results take 48-72 hours [2], and lack sensitivity: up to 70% of pneumonia 
patients have no pathogen identified [10]. Consequently, many patients remain on 
empirical treatment and, if the causative organism is drug-resistant, this may be 
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ineffective. More often, however, empirical antibiotic treatment is overly broad- 
spectrum, representing unnecessary use of valuable ‘last-resort’ antibiotics. Given 
increasing emphasis on antibiotic stewardship, and possible improved outcomes, the 
National Institute for Health and Care Excellence (NICE) and the Infectious Diseases 
Society of America (IDSA) have recommended research into rapid molecular 
diagnostic tests for identifying causative organisms and antibiotic resistance profiles 
[2, 11]. Ideally, these would augment/replace culture, as they are quicker (1-6 hours) 
and believed more sensitive [12, 13]. 
The UK’s National Institute for Health Research (NIHR)-funded INHALE programme 
is exploring use of molecular diagnostics to inform HAP/VAP treatment in critical 
care [14-17]. Currently, INHALE is comparing antibiotic use and outcomes in a trial 
where HAP/VAP patients are randomised to standard care (i.e. empirical antibiotics, 
refined once culture results become available) or to treatment guided by the 
BioFire® FilmArray® (utilising the Pneumonia Panel – see Buchan et al. [12] and 
Murphy et al. [13] for further information), which identifies common pneumonia 
pathogens and critical antimicrobial resistance genes within 75 minutes. 
Wider deployment of such diagnostics has resource implications, particularly for 
resource-intensive critical care, where HAP/VAP primarily occurs. It is important to 
look beyond test effectiveness, to consider associated resource impacts and any 
corresponding costs/savings. Accordingly, INHALE includes a health economic (HE) 
component, comparing cost and outcomes under the treatment alternatives. 
Economic evaluations alongside trials have limitations [18]: short time horizons 
(meaning that ultimate costs and benefits are not fully captured); inability to consider 
all relevant options and limited generalisability. Therefore, an economic model will be 
constructed to extrapolate beyond the trial and to allow exploration of various 
scenarios. 
Considerable information is required in constructing HE models, including the 
following. First, the research question that the model is designed to address; this can 
vary from narrow (e.g. comparison of a new intervention against existing care) to 
wider questions (e.g. whole disease-based models that evaluate multiple 
interventions). Second, the model structure, defining the different health states or 
events occurring within the model and how they interact. Third, model perspective 
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(e.g. secondary care only), determining the required range of information. Fourth, the 
model’s timeframe: what period should it capture to include important costs and 
benefits? These factors influence required data. 
Prior to INHALE’s trial, we conducted a literature review to identify studies that 
constructed a health economic model relating to HAP or VAP. We had two broad 
objectives. First, to identify the context in which the health economic modelling had 
been undertaken (i.e. the research question(s) the modelling was addressing). 
Second, and more importantly, to summarise model structures, modelling 
perspectives and timeframes. 
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2.1 Literature search 
Embase Ovid and MEDLINE Ovid databases, along with the National Health Service 
Economic Evaluation database (NHS EED), were searched on 5/4/17 to identify 
articles that: 
• Contained economic modelling; 
• Focused on pneumonia acquired in hospital. 
 
When searching Embase and MEDLINE, terms from both components were used 
(Supplementary materials, Appendix 1); searching the NHS EED database, which 
only includes health economic studies, did not require economic modelling terms. 
The single term ‘pneumonia’ was used to search the latter database. Searches were 
restricted to English language articles. 
The Embase/Medline search was updated on the 4/6/2020 to identify any recently 
published work. The NHS EED search was not repeated since that database has not 
been updated since the initial search – see [19]. 
 
 
2.2 Eligibility criteria and selection of studies 
Studies were considered for inclusion if they: 
• Related to the treatment or management of HAP or VAP; 
• Included an economic model; 
• Were undertaken in, and pertinent to, a hospital setting. 
 
Studies were excluded if they: 
• Were not in the English language; 
• Were just abstracts; 
• Only considered community-acquired pneumonia (CAP); 
• Focused on prevention rather treatment of HAP/VAP; 
• Considered HAP/VAP as management outcomes, without specific treatments. 
 
 
For the first and the subsequent searches, records from the Ovid 
(Embase/MEDLINE) search were considered first. Duplicates were removed; titles 
and abstracts of the remaining records were then independently screened for 
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eligibility by two reviewers, using a pre-piloted checklist. This was repeated with the 
NHS EED search results. Duplicates already identified in the Ovid 
(MEDLINE/Embase) search were then removed 
 
Reference lists of included studies were screened for additional eligible studies. 
 
 
2.3 Data extraction 
Data extracted were: study characteristics, models and economic evaluations. Study 
characteristics included: authorship; journal; country of study; population; costing 
year; comparators/study groups; and any industry funding links. Characteristics of 
the model and economic evaluation included: costing perspective; outcome 
measure; model type; time horizon; cost discount rate; Quality Adjusted Life Year 




2.4 Health economic concepts 
The costing perspective relates to the breadth of costs considered: this can be 
narrow (e.g. secondary care costs), or broad, including wider perspectives (e.g. at 
the broadest, ‘costs to society’). A narrow perspective can be problematic when 
important costs arise because of an intervention but are not captured (e.g. adopting 
a narrow secondary care perspective in respect of a hospital intervention will miss 
possibly large impacts on primary care). ‘Discount rate’ refers to how costs and 
benefits were adjusted to allow for differences in when they occur, with events 
occurring further into the future valued less. ‘Sensitivity analysis’ (SA) covers 
different ways in which uncertainty is accommodated in models, and explores the 
impact on results of varying key parameters [20]. Simple ‘one-’ or ‘two- way SA’ 
varies one or two parameters within a set value range and notes resulting impacts on 
results and model conclusions. SA can include threshold analysis, in which 
parameters are varied to determine the value where a “‘threshold’ is reached, for 
example a change of model conclusions” [21, p.56]. SA can also include scenario 
analysis, where a number of model parameters are set to reflect particular scenarios; 
for example, best/worst cases. More sophisticated forms of SA includes ‘Probabilistic 
Sensitivity Analysis’ (PSA), which uses probability distributions to model the 
uncertainty around point estimates of multiple model parameters simultaneously [22]. 
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Incremental cost-effectiveness ratios (ICERs) are reported for some studies: these 
are “a summary measure representing the economic value of an intervention, 
compared with an alternative,” and are “calculated by dividing the difference in total 
costs (incremental cost) by the difference in the chosen measure of health outcome 
or effect (incremental effect) to provide a ratio of ‘extra cost per extra unit of health 
effect’” [23]. 
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3.1 Study selection process 
The flow chart (Supplementary materials, Figure S1) depicts the number of records 
retrieved, screened for eligibility, and the numbers of exclusions/inclusions. Overall, 
698 records were identified from databases and two more were found [24, 25] 
through screening reference lists. Following removal of 80 duplicates, 592 records 
deemed ineligible at initial screening, and six [26-31] deemed ineligible during full 
text review, 20 valid studies were identified. 
 
 
3.2 General characteristics of included studies 
Key details of the 20 selected publications are in Table I. Only one was published 
before 2000 [32]; seven [24, 33-38] were published between 2001 and 2006, and 
twelve [25, 39-49] between 2009 and 2019. The USA was the most-represented 
country (n=13) [24, 25, 32, 35-39, 42, 44, 47-49], with two studies in Germany [40, 
45], and one in each of: Brazil [34]; China [46]; Spain [33]; Taiwan [43] and the UK 
[41]. 
Studies differed in patient populations considered. Six studies considered HAP/VAP 
broadly [24, 33, 36, 39, 42, 44], whereas the remaining studies focused on HAP 
and/or VAP caused by specific pathogens, especially Methicillin-resistant 
Staphylococcus aureus (MRSA). Six only considered VAP [24, 35, 36, 43, 45, 47]. 
The most common interventions evaluated (n=15) were simple comparisons 
between pairs of antibiotics. In seven studies, antibiotics were used from the empiric 
treatment phase [34, 39, 40, 43, 44, 46, 47]; three after the empiric phase [25, 41, 
45]; for five it was unclear [33, 35, 38, 42, 48]. The systematic review by Zhang et al. 
[49] compares vancomycin against five other antibiotics (linezolid; teicoplanin, 
telavancin; quinupristin/dalfopristin; trimethoprim/sulfamethoxazole/rifampicin) for 
treating HAP due to MRSA. Three of the remaining four studies focused on single 
antibiotics. Shah et al. [37] estimated the cost of treating HAP caused by MRSA with 
the antibiotic vancomycin. Paladino et al. [32] compared ‘dual individualization’ 
(where ‘Antibiotic [cefmenoxime] regimens are manipulated to optimize the area 
under the plasma concentration time curve above the minimum inhibitory 
concentration [MIC] of [sic.] the infecting bacteria’ [32, p.384]) – however, it is 
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important to note that cefmenoxine is no longer used and that time above MIC is the 
driver of -lactam efficacy rather than area under the concentration time curve. 
McNabb et al. [24] compared continuous versus intermittent infusion of ceftazidime. 
Ost et al. [36] is the only study that compared different diagnostic and treatment 
strategies, focusing on VAP with 16 combinations arising from four diagnostic 
options [nothing; bronchoscopy; quantitative culture of unprotected ETT aspirate; 
quantitative cultures of protected specimen blind mini-bronchoalveolar lavage (mini- 
BAL)] and four initial antibiotic treatment options (none, one, two, or three agents). 
The model did not consider specific named antibiotics, but rather used expected 
coverage rates when guidelines [50] were applied to sample late-onset VAP cases 
[51]. See Ost et al. [36] supplementary materials for further detail. 
 
 
3.3 Modelling approaches and scope 
Details and results of models are in Table II. A range of outcomes were considered 
across studies, and some studies used multiple outcomes. The most commonly used 
outcomes included: survival [34-36, 38, 40, 42, 47]; clinical cure rate [24, 25, 40, 43, 
45, 46, 48]; QALYs [33, 38, 39, 41, 47]; and life years gained [33, 38, 40, 47, 49]. 
Two studies [37, 44] only considered costs, with no consideration of outcomes: Shah 
et al. [37] only considered the costs of treating with vancomycin, with no comparator, 
precluding cost-effectiveness conclusions; McGarry et al. [44] justify their analysis as 
cost-minimisation since ‘the two comparators [doripenem and imipenem] were found 
to be equally safe and efficacious’ [44, p.143]. Other outcomes included: duration of 
antibiotic therapy while in hospital [32]; length of stay [42]; proportion of admission 
spent in an intensive care unit (ICU) [42]; and proportion (denominator unclear) of 
time on a ventilator [42]. There is an approximate even split between studies in the 
choice of costing perspective: nine adopted a healthcare payer perspective [25, 35, 
38, 39, 42-46] and ten adopted a healthcare system perspective [24, 32-34, 36, 37, 
40, 41, 48, 49]. Zilberberg et al. [47] adopted a healthcare system and a societal 
perspective; this was the only study to consider a societal perspective. 
Most (n=18) studies used a decision tree model. One used discrete event micro- 
simulation [42] (`a computer-modelling technique … in which individual patient 
experience is simulated over time, and events occurring to the patient and the 
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consequences of such events are tracked and summarised’ [52]). Another study 
used a Markov cohort model (where specific health states are defined and 
movement between these is modelled) [41]. It was difficult to categorise time 
horizon: some studies were not explicit (e.g. ‘until cure’ [40]). However, several gave 
a specific duration in days [25, 33, 38, 39, 41-43, 45, 46]. Only six ran the model for 
the lifetime of participants [33, 38, 39, 41, 47, 49]. Except for Machado et al. [34], SA 
was conducted in all studies. Sixteen studies used one- or two- way sensitivity 
analyses. Ten studies used PSA [25, 36-39, 41, 44, 45, 47, 49]. 
3.4 Modelling results reported by studies 
Nine studies [25, 33, 34, 38-40, 43, 45, 46] solely compared linezolid to vancomycin. 
At the time of the analyses linezolid was proprietary. Of these, only two did not have 
exclusive focuses on particular pathogen subsets: Collins and Schwemm [39] found 
linezolid to be cost-effective for HAP treatment with a life-time horizon; Grau et al. 
[33] found linezolid to be cost-effective for VAP. 
 
All but two [38, 39] of the nine studies considered MRSA HAP/VAP: four found 
linezolid to be cost-effective [33, 40, 43, 46]; and three found linezolid to be less 
costly and more effective [25, 34, 45]. These conclusions for treating MRSA HAP 
accord with those reached by Zhang et al. [49], who include vancomycin and 
linezolid amongst a number of comparators. These authors conducted a meta- 
analysis of clinical studies (incorporating those that provide data for the seven MRSA 
HAP/VAP studies noted above), and incorporated them in an economic model: 
linezolid was found to have an ICER of $2,185 per additional life year saved 
compared with vancomycin – a gain that was very likely to be considered cost- 
effective. Of the other treatments considered by Zhang et al. [49], teicoplanin was 
found to dominate (cost saving and more effective) vancomycin, but the limited 
clinical evidence was judged weak. The other antibiotics evaluated by Zhang et al. 
[49] were not considered cost-effective compared to vancomycin (ICERs per life year 
saved were >$50,000). 
Two studies considered other subsets of HAP pathogens: Shorr et al. [38] 
considered VAP attributed to Staphylococcus aureus in general, and found linezolid 
to be cost-effective; Grau et al. [33] found linezolid to be cost effective for treating 
VAP caused by Gram-positive bacteria. 
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Linezolid and vancomycin are only active against Gram-positive infections and five 
studies focused solely on cases where these organisms were confirmed [25, 34, 43, 
45, 46]; four studies drew on clinical trials where patients received aztreonam for 
Gram-negative coverage, but either did not consider its costs in their model [38-40] 
or excluded patients with Gram-negative infections [33]. 
In considering linezolid and vancomycin comparisons, undertaken a decade or 
longer ago, it is important to note the substantial context change: linezolid is now out 
of patent and substantially less costly to purchase. 
A more recent study [48] compares first line telavancin to vancomycin for treating 
HAP caused by Staphylococcus aureus. The model considers both MRSA and 
Methicillin-sensitive Staphylococcus aureus (MSSA), with different treatment 
approaches for each. Telavancin was found to have a higher cure rate, but at an 
increased cost, with an ICER of $4,156 per additional cure. 
Four studies [35, 42, 44, 47] compared doripenem and imipenem. They concluded 
doripenem was preferable, given similar efficacy, and being cost-saving in two 
studies [42, 44] and having a relatively low ICER for additional benefits in the others 
[35, 47]. However, these results are no longer relevant as doripenem was 
subsequently found to have higher mortality in HAP/VAP [53] and its European 
license was withdrawn. Edwards et al. [41] found meropenem to be more effective 
and cost-saving compared with piperacillin/tazobactam in HAP patients not 
responding to first-line antibiotics. 
Ost et al. [36], compare diagnostic and treatment options across three dimensions: 
cost; antibiotic use; and survival. Initial treatment with three antibiotics was optimal 
for cost and survival. Mini-BAL testing did not improve survival, but decreased costs 
and antibiotic use. Across all three domains, mini-BAL with three antibiotics was 
optimal. 
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Our review identified 20 studies that applied economic modelling to the treatment of 
HAP and/or VAP. Only one model [36] specifically evaluated strategies to improve 
HAP/VAP diagnosis, meaning that most models reported had little direct relevance to 
the evaluation of a rapid molecular diagnostic test for microbiological investigation of 




4.1 Conclusions of studies and generalisability 
Most studies compared two antibiotics and of these, most were undertaken in 
connection with the launch of then-new products, linezolid and doripenem. Such 
comparisons do not necessarily require complex models: e.g. Machado et al. [34] 
has one decision node to choose antibiotic, and a chance node for therapy success. 
Many studies focused on MRSA and other Gram-positive pathogens, limiting 
relevance, as approximately two-thirds of HAP/VAP cases involve Gram-negative 
pathogens [4]. Studies relating to single pathogens (e.g. MRSA) have limited scope 
to represent the typical situation faced by clinicians treating HAP where the 
causative pathogen is unknown. 
Most models considered a short-time frame, typically until resolution, with only six 
models considering a longer, life-time, time horizon. Most captured the patient 
‘journey’ until case resolution – generally being cure or death – meaning 60 days or 
less. This likely undervalues benefits from more successful treatments (e.g. if 
measuring in QALYs, the value of saving a life will be much greater if considering a 
life-time horizon rather than only until case resolution). Moreover, those models that 
do capture longer time-frames and QALYs typically do so in a simplistic way, using 
strong assumptions rather than long-term follow-up. Thus, five of the six studies [33, 
38, 39, 47, 49] adopting a life-time horizon have broadly adopted the same strong 
assumptions, in particular that survival post VAP is similar to that observed in sepsis 
survivors. Another assumption used to estimate QALYs draws on evidence that 
survivors of acute respiratory failure requiring ventilation have their quality of life 
reduced by 8% [46]: accordingly, post-discharge QALYs are reduced from 1 to 0.92 
[37]. Some authors have further reduced this to 0.83 [33, 38, 47]. An alternative 
approach assumes that, once discharged, patients ‘accrued their normal age- and 
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sex-adjusted HRQL [health-related quality of life]’ [41, p.185-186]. The importance of 
long-term data for decision making is illustrated by estimates of the cost- 
effectiveness of linezolid compared to vancomycin, which has a cost per additional 
QALY estimated at $19.6million [resulting from dividing an incremental cost ($892) 
by a very small incremental QALY gain (<0.001)] over 60 days, decreasing to $6,089 
with a life-time horizon [39]. 
4.2 Model sophistication and implications for economic modelling of rapid diagnostics 
We found variation in model sophistication, though most models tended towards 
simple structures. Only two models did not use decisions trees, with one using a 
Markov model [41] and one using a discrete event micro-simulation model [42]. 
Additionally, the model by Edwards et al. [41] was the only one to incorporate 
different hospital settings such as ICU and wards, potentially supporting more 
precise costings. 
Among decision trees, the simplest was that of McNabb et al. [24] and Machado et 
al. [34] consisting of a decision node choosing between treatment alternatives 
(vancomycin or linezolid) and a chance node representing treatment outcome (cure 
or death). The model in Mullins et al. [35] is more complex, with four outcomes: 
survival with bacteraemia; survival without bacteraemia; death with bacteraemia; and 
death without bacteraemia. The model of Zhang et al. [49] deals with three 
outcomes: cure, death and treatment switch following initial treatment failure. Its 
simplicity is likely a result of synthesising a literature review and comparing a 
relatively large (five) number of alternatives to vancomycin: more sophistication 
would require very strong assumptions. A subset of more sophisticated models have 
an additional level of chance nodes: the first chance node captures treatment 
success, followed by another node modelling either survival [33] or adverse event 
occurrence [32, 43]. Among the two most sophisticated decision trees were found in 
the later studies by De Cock et al. [40], Patel et al. [45], Patel et al. [25] and Tan et 
al. [46] ([45], [25] and [46] use the same model structure). Both models capture a 
wide range of outcomes: cure, adverse event, lack of efficacy and death. 
Additionally, both models more closely follow clinical practice by capturing switching 
antibiotics when the ‘first line’ agents prove ineffective. The model used in the papers 
by Patel et al. [45], Patel et al. [25] and Tan et al. [46] is less generalizable given 
they focus on confirmed MRSA HAP, while the model in De Cock et al. [40] 
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incorporates nodes relating to determining infection cause. Another more 
sophisticated tree is used in McKinnell et al. [48]: focusing on HAP due to 
Staphylococcus aureus, it explicitly models cure and adverse event (nephrotoxicity) 
occurrence, along with causative subset of Staphylococcus aureus (MRSA or not; 
mono- or poly-microbial), but does not explicitly address death or treatment switching 
(patients not achieving cure with the first-line treatment were assumed cured 
following switching to linezolid for seven days). 
There are two other decision tree models. Zilberberg et al. [47] present a model that 
seems to be ill-formed: chance nodes have perhaps been confused with decision 
nodes. The decision tree of Ost et al. [36] is the most relevant for informing a model 
to evaluate rapid diagnostics: there are two decision nodes for choosing between 
diagnostic tests and number of initial antibiotics. They also capture antibiotic 
switching if needed and consider a range of outcomes, but do not explicitly address 
adverse events. Ost et al. [36] is also the only model that explicitly captures the 
empiric treatment phase. 
4.3 Limitations 
For this literature review we searched three databases, selected for their 
comprehensive, international biomedical (Embase Ovid and MEDLINE Ovid) and 
speciality health economic coverage (NHS EED) [19]. Additional eligible studies 
might have been identified had we broadened the search to additional databases 
such as: EconLit [54]; HEED [55]; and HTA [56]. However, our aim was to identify 
studies to inform economic modelling in this area. This contrasts with systematic 
reviews of effectiveness studies, where the intention is to derive a pooled estimate of 
effect, within which the aim is to identify as many eligible studies as possible to help 
reduce bias. We have not assessed studies for risk of bias or quality. 
 
5 Conclusions 
We found 20 studies using economic modelling in HAP/VAP treatment. Only one – 
Ost et al. [36] – compares different diagnostic approaches, making it the most 
relevant for informing our model evaluating rapid diagnostics for treating HAP. Most 
models used simple decision trees, short time horizons, and assumed a known 
pathogen. The clinical utility of future work would be improved by considering long- 
term outcomes and increased awareness of the complex reality of HAP/VAP 
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treatment, in particular, explicitly addressing the commonly occurring situation where 
the causative organism is initially unknown. 
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Table I: Characteristics of HAP or VAP studies involving economic modelling. 
































De Cock et al. 
[40], 2009 
Infection Germany 
HAP (suspected/ proven 
MRSA) 
2006 




Edwards et al. 
[41], 2012 




HAP (severe, ICU treated, post failed 














VAP (all, Gram +ve, S. aureus, 
MRSA) 
2003 
Antibiotics: linezolid vs 
vancomycin (unclear if empiric) 
Pfizer 
Kongnakorn et 
al. [42], 2010 
Current Medical 
Research & Opinion 
US HAP 2007 
Antibiotics: doripenem vs 





















Machado et al. 
[34], 2005 
Brazilian Journal of 
Infectious Disease 
Brazil VAP (MRSA) 2004 
Antibiotics: linezolid vs 
vancomycin (empiric) 
NR 
McGarry et al. 
[44], 2010 
Journal of Medical 
Economics 
US VAP (diagnosis) 2006 











HAP (Staphylococcus aureus) 
 
2016 
Antibiotics: telavancin vs 




McNabb et al. 
[24], 2001 
Pharmaco-therapy US HAP 1999 
Treatment: continuous v 
intermittent Ceftazidime dosing 
NR 
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Mullins et al. 
[35], 2006 
Clinical Therapeutics US HAP (MRSA) NR 
Antibiotic: doripenem vs 




Ost et al. [36], 
2003 
 













Management strategies - 16 
options: 4 diagnostics (nothing; 
bronchoscopy; quantitative culture of 
unprotected ETT aspirate; quantitative cultures 
of protected specimen blind mini- 
bronchoalveolar lavage (mini-BAL)) with 4 




Merck & Roche 







HAP (Gram -ve) 
 
1992 
Treatment: individual tailoring vs 




Patel et al. [25], 
2014 
Critical Care US HAP (MRSA confirmed) 2012 
Antibiotics: linezolid vs 
vancomycin (post culture) 
Pfizer 
Patel et al. [45], 
2014 
Infection and Drug 
Resistance 
Germany HAP (MRSA confirmed) 2012 
Antibiotics: linezolid vs 
vancomycin (post culture) 
Pfizer 
Shah et al. [37], 
2004 
Current Medical 
Research & Opinion 
US HAP (MRSA)* 2003 NA Cubist Pharma 




US VAP (Staphylococcus aureus) 2001 
Antibiotics: linezolid vs 
vancomycin (unclear if empiric) 
NR 
Tan et al. [46], 
2014 
Value in Health 
Regional Issues 
China HAP (MRSA confirmed) NR 




















Antibiotics: vancomycin vs. each 








Zilberberg et al. 
[47], 2010 








* Shah et al. [37] also considers: skin and soft tissue Infections; bacteraemia; infective endocarditis. We only consider HAP here. 
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Table II: Modelling details and results of identified economic models in the area of HAP and VAP. 
Key: VAP= ventilator associated pneumonia. PSA= probabilistic sensitivity analysis. ICER= incremental cost effectiveness ratio. QALY= quality adjusted 
life year. HAP= hospital acquired pneumonia. LOS= length of stay. MRSA= methicillin resistant Staphylococcus aureus. ICU= intensive care unit. NA= not 



























































Lifetime horizon ICER per: QALY= $6,089; 
life saved= $68,615. Vancomycin 
dominated in documented cases of MRSA. 
60-day horizon ICER per: QALY= 
$19,608,688; life saved= $443,662. Model 
sensitive to changes in: mortality; 
population; and time horizon. 
 
De Cock et 













Cure on either 
1st- or 2nd-line 
treatment, or 













ICERs: per life gained= €180; per death 
avoided= €3,171; per additional cure= 
€4,813. In scenarios, linezolid dominates. 
Consistent under sensitivity analyses. 
 
Edwards et 













as no costs 





Meropenem dominated (PSA: meropenem 
dominated in 94% of simulations). 
Consistent under sensitivity analyses. 
 
 
































ICER per life year saved: all VAP= €1,501; 
Gram +ve VAP= €827; S. aureus VAP= 
€955; MRSA VAP= €289. ICERS per life 
year saved: all VAP= €1,804; Gram +ve 
VAP= €997; S. aureus VAP= €1,149; MRSA 
VAP= €349. Base case consistent under 
sensitivity analyses. 
Kongnakorn 






LOS; % time 












as no costs 







Similar relapse and death rates. LOS (days): 
doripenem= 16.0; imipenem= 18.9. Doripenem 
gave $7,000 in savings per patient (driven by 
reduction in LOS). Consistent under sensitivity 
analyses. 
INHALE lit review AW DT RevResp v3 10.08.2020_NO_TC.docx 




















































ICER per cured person $3,421 (PSA 95% 



































Cure rate: linezolid= 62.2%; brand-name 
vancomycin= 21.2%; generic vancomycin= 
21.2%. Invested amount per cured 
patient: linezolid= R$7,765; brand-name 



























Average doripenem costs were $10,630 


































ICERs: per additional cure= €4,156. In 
scenario (monomicrobial infections only) 
telavancin dominates. ICER sensitive to 
probabilities of cure, length of treatment 
in cures, ICU cost, telavancin cost, and 
additional length of stay due to failure. 
 
McNabb et 


















as no costs 







Cure rate: continuous infusion= 94%; 
intermittent= 83%. Costs (significantly 
different): continuous infusion= 
$627±388; intermittent= $1,007±430. 


















ICER per life year saved= $3,600. 
Consistent under sensitivity analyses. 
 
 
















Time to: death 
due to VAP; 















Use of 3 antibiotics was better than 0-2 
antibiotics, giving improved survival (54% vs. 
66%) and decreased cost ($55,447 vs. $41,483 
per survivor). Mini-BAL testing did not improve 
survival but decreased costs ($41,483 vs. 
$39,967) and antibiotic use (63 vs. 39 antibiotic 
days per survivor). 3 antibiotics with mini-BAL 
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ICER antibiotic days reduced=$114. 
Median antibiotic duration days: 12.7 dual 
individualisation; 15.2 standard 
treatment. 
 


























Linezolid dominates (by $824 and 2.7% 
greater cure rate). Consistent under 
sensitivity analyses (at a WTP of €0, 
linezolid has a 64.4% chance of cost- 
effectiveness). 
 


























Linezolid dominates (by €123 and 2.7% 
greater cure rate). Consistent under 
sensitivity analyses (at a WTP of €0, 
linezolid has a 53.9% chance of cost- 
effectiveness). 
 






















Base case cost of treating 
HAP=$22,493/patient (PSA gives mean 
and 95% CI of $22,511±3,689). 
 



























ICER per: survivor= $67,202; Life years 
saved= $22,072; QALY= $29,945. 
Consistent under sensitivity analyses. 
 

























ICER per additional successfully treated 
patient: Beijing= ¥1,861; Nanjing= ¥163; 
Xi'an= ¥16,509. Linezolid dominates in 
Guangzhou. Consistent under sensitivity 
analyses. 
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Compared to vancomycin: not cost-effective 
(ICER per LY gained>$50,000) - telavancin, 
quinupristin/dalfopristin, trimethoprim/ 
sulfamethoxazole/rifampicin; cost-effective - 
linezolid (ICER per LY gained=$2,185); 
teicoplanin dominant but discounted (draws 
on one 'high risk' study). Results most sensitive 
to antibiotic costs and treatment duration. 
Telavancin unit costs <$320 would make it 
more cost-effective than linezolid. Other single 






















system - time 




















ICER per: death averted= $127,178 (PSA 
95% CI= -$136,534 to $568,281); LYS= 
$9,276 (PSA 95% CI= -$11,254 to $21,579); 
QALY= $5,748 (PSA 95% CI= -$6,923 to 
$13,904). Consistent under sensitivity 
analyses. 
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Figure S1: Process of article identification. Adapted from Moher et al. [57]. 
Key: NHS EED= National Health Service Economic Evaluation database. 
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Appendix: Ovid Medline and Embase search strategy with result hits 
 
 OVID Medline and EMBASE search conducted: 05/04/2017 04/06/2020 
1 Markov chain [Including Limited Related Terms] 5194 9177 
2 Decision support techniques [Including Limited Related Terms] 3232 9013 
3 (econom* adj2 model*).ti,ab. 11373 12672 
4 (markov* adj5 model*).ti,ab. 30819 36072 
5 (decision* adj8 model*).ti,ab. 44774 50405 
6 (discrete event* adj8 model*).ti,ab. 1458 1649 
7 (Discrete event* adj5 simulat*).ti,ab. 1813 2015 
8 Microsimulat*.ti,ab. 2121 2948 
9 or/1-8 89976 108339 
10 "hospital acquired pneumonia".mp. 6420 5128 
11 hospital acquired pneumonia [Including Limited Related Terms] 4528 7598 
12 "hospital-acquired pneumonia".mp. 6420 5128 
13 HAP [Including Limited Related Terms] 2283 3377 
14 ventilator associated pneumonia [Including Limited Related Terms] 6125 11687 
15 "ventilator associated pneumonia".mp. 24369 17648 
16 VAP.mp. 15739 11926 
17 HAP.mp. 12881 12324 
18 VAP [Including Limited Related Terms] 10015 6568 
19 nosocomial pneumonia [Including Limited Related Terms] 4528 7598 
20 nosocomial pneumonia.mp. 10235 5777 
21 hospital acquired bacterial pneumonia [Including Limited Related Terms] 4436 5990 
22 "hospital acquired bacterial pneumonia".mp. 117 96 
23 "ventilator acquired bacterial pneumonia".mp. 2 10 
24 ventilator acquired bacterial pneumonia [Including Limited Related Terms] 4874 8935 
25 healthcare associated pneumonia [Including Limited Related Terms] 938 1115 
26 ((healthcare adj3 associated) and pneumonia).mp. 4943 3021 
27 (rapid adj3 diag*).mp. 64730 49527 
28 (molecular adj3 diag*).mp. 87011 75046 
29 or/27-28 147225 121622 
30 or/10-26 70040 56014 
31 and/29-30 1090 435 
32 (bacter* and (infection$ or pneumonia$)).mp. 1278017 1114821 
33 29 and 32 19907 11600 
34 30 or 33 89077 67313 
35 9 and 34 225 203 
36 35 225 203 
37 limit 36 to english language 222 200 
38 limit 37 to yr=2017-2020 NA 54 
 
Terms 1-9 terms relate to economic modelling and are taken from Edlin et al. [58]. Terms 10-26 are 
used to identify HAP or VAP. The rapid diagnostic device terms (terms 27 and 28) were included to 
find items for use elsewhere; we do not consider rapid diagnostics in this article. 
Term 38 not in search conducted on 05/04/2017 search as this search was not date limited 
